NCT06265428
A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer
At risk: Primary completion moved at least 1 year 9 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from Feb 2026 to Dec 2027 Show 4 more changesShow less
- Eligibility criteria expanded, about 12 words
- Study completion pushed from Feb 2026 to Dec 2028
- Interventions: DB-1303/BNT323 (Drug), T-DM1 (Drug) to DB-1303/BNT323 (Drug), T-DM1 (Drug)
- Secondary endpoints: details revised at 8 of 12 entries
- Minor Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 224 to confirmed 228
- Site details revised at 48 of 48 sites
- Minor Study sites: 2 to 48v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) assessment per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
Timeframe: Up to approximately 24 months.
Secondary (12)
Overall Survival (OS)
Progression Free Survival (PFS) by Investigator assessment per RECIST 1.1
Objective response rate (ORR) by BICR and investigator assessment per RECIST 1.1
Duration of response (DoR) by BICR and investigator assessment per RECIST 1.1
PK parameters: maximum observed concentration (Cmax)
Show 7 moreShow less
PK parameters: time to maximum concentration (Tmax)
Adverse events (AEs)
Patient reported outcomes (PROs): European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) - C30
Patient reported outcomes (PROs): EORTC QLQ-BR45
Patient reported outcomes (PROs): European Quality of Life Five Dimension Five Level Scale (EQ-5D-5L)
European Quality of Life Five Dimension Five Level Scale (EQ-5D-5L)
Anti-drug antibodies (ADA)
Arms and interventions
DB-1303/BNT323Experimental
Enrolled patients will receive DB-1303/BNT323 by intravenous (I.V.) infusion
T-DM1Experimental
Enrolled patients will receive T-DM1 by I.V. infusion
Drugs: DB-1303/BNT323, T-DM1
Sites
48 sites in 1 country